Bio-Gene Technology

Bio-Gene Technology FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Bio-Gene Technology (BGT.AX) as of Oct 20, 2026 is 166.35 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 98.39 % — a change of 69.08% (higher).

FCF Conversion

166.35 %

YoY

69.08%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Bio-Gene Technology is 2026 166.35 % . FCF Conversion Rate (FCF/EBITDA) of Bio-Gene Technology was 2025 98.39 % . It decreases by 69.08% higher compared to the previous year.

The Bio-Gene Technology FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
114.82 AUD
Jan 1, 2020
85.24 AUD
Jan 1, 2021
76.31 AUD
Jan 1, 2022
-1.26 AUD
Jan 1, 2023
105.83 AUD
Jan 1, 2024
114.56 AUD
Jan 1, 2025
98.39 AUD
Jan 1, 2026
166.35 AUD
The Bio-Gene Technology FCF Conversion history
YEARFCF ConversionYoY
166.35 %+69.08%
98.39 %-14.12%
114.56 %+8.25%
105.83 %-8,509.47%
-1.26 %-101.65%
76.31 %-10.48%
85.24 %-25.76%
114.82 %+24.49%
92.23 %+32.53%
69.59 %-49.83%
138.71 %-12.05%
157.71 %+180.47%
56.23 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Bio-Gene Technology Stock analysis

What does Bio-Gene Technology do? Bio-Gene Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio-Gene Technology stock

FCF Conversion Rate (FCF/EBITDA) of Bio-Gene Technology is 166.35 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Bio-Gene Technology changed from 98.39 % to 166.35 %, representing a 69.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Bio-Gene Technology since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Bio-Gene Technology with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Bio-Gene Technology

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Bio-Gene Technology